The article examines the objective, findings, and clinical context described in FDA Grants Temab-A Dual Breakthrough Status.
Approach:
CRC designation: Temab-A plus bevacizumab received designation for adults with refractory metastatic colorectal cancer previously treated with specified chemotherapy and biologic regimens.
NSCLC designation: Temab-A monotherapy received designation for previously treated adults with locally advanced or metastatic EGFR wild-type, c-Met protein–expressing, nonsquamous NSCLC.
Evidence base: The designations were based primarily on findings from the ongoing first-in-human phase 1 M21-404 trial.
Key Findings:
In a CRC dose-expansion analysis, confirmed objective response was 27% among 30 patients receiving Temab-A 2.4 mg/kg plus bevacizumab, versus 0% among 20 evaluable patients receiving trifluridine/tipiracil plus bevacizumab; the 2.0-mg/kg Temab-A combination ha…
Investigators identified 2.4 mg/kg as having the most favorable benefit-risk profile. Grade 3 or higher treatment-emergent adverse events occurred in 67% with this Temab-A combination and 65% with standard-of-care therapy.
Common adverse events with Temab-A 2.4 mg/kg plus bevacizumab included anemia (63%), nausea (60%), neutropenia (53%), fatigue (43%), and vomiting (40%). Treatment-related adverse events led to discontinuation in 3% and 10% of patients, respectively.
In a separate NSCLC dose-expansion cohort of 48 patients, grade 3 or higher treatment-emergent adverse events occurred in 63%; hematologic and gastrointestinal events were most common overall.
Interpretation:
Breakthrough Therapy Designation is intended to expedite development and review when preliminary clinical evidence suggests potential substantial improvement over available treatment on a clinically significant endpoint. It is not FDA approval; Temab-A remains investigational.
Limitations:
The evidence described comes from an ongoing phase 1 study and dose-expansion analyses.
The CRC comparison included 30 patients in the 2.4-mg/kg Temab-A group and 20 evaluable patients in the standard-of-care group; patients were not selected by c-Met expression.
The provided NSCLC results report safety findings but do not provide response or survival outcomes.
